Shield Therapeutics (LON:STX) Trading Up 30.2% - Here's Why

Key Points

• Shield Therapeutics shares rose by 30.2% during trading, reaching a high of GBX 8.90 ($0.12) from a previous close of GBX 6.30 ($0.08).
• Over 25 million shares were traded, which is an 879% increase from the average session volume.
• The company, known for its Accrufer®/Feraccru® product addressing iron deficiency, currently has a market capitalization of £90.47 million.

Shares of Shield Therapeutics plc (LON:STX - ) traded up 30.2% during trading on Friday . The stock traded as high as GBX 8.90 ($0.12) and last traded at GBX 8.20 ($0.11). 25,560,381 shares traded hands during mid-day trading, an increase of 879% from the average session volume of 2,610,317 shares. The stock had previously closed at GBX 6.30 ($0.08).

Shield Therapeutics Stock Up 5.9%

The stock has a 50 day moving average of GBX 4.88 and a 200-day moving average of GBX 3.48. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a market capitalization of £90.47 million, a P/E ratio of -434.25 and a beta of 1.42.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.